Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2022 Aug 25

PMID 36005198

Authors

Urska Janzic

Nina Turnsek

Mircea Dediu

Ivan Shterev Donev

Roxana Lupu

Gabriela Teodorescu

Tudor E Ciuleanu

Adam Pluzanski

Affiliations

Soon will be listed here.

Abstract

The targeted therapy with tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor mutation (EGFRm) in advanced non-small cell lung cancer (NSCLC) changed the treatment paradigm. REFLECT study (NCT04031898) explored / testing and treatment patterns in EGFRm NSCLC patients receiving first- or second-generation (1G/2G) EGFR TKIs as front-line (1L) in eight countries. Pooled data from Central Eastern Europe (CEE) countries from this study (Bulgaria, Poland, Romania, Slovenia) are presented here. This physician-led chart review study was conducted in patients with confirmed-EGFRm NSCLC initiating 1L 1G/2G EGFR TKIs between 2015-2018. The CEE cohort included 389 patients receiving 1L erlotinib (37%), afatinib (34%), and gefitinib (29%). Overall, 320 (82%) patients discontinued 1L, and 298 (77%) progression events were registered. Median progression free survival on 1L TKIs was 14.0 (95% CI: 12.6-15.6) months. Median overall survival from 1L start was 26.6 (95% CI: 24.1-29.0) months. Attrition rate between 1L and next line was 30%. Among patients with 1L progression, 200 (67%) were tested for and 58% were positive. This first CEE analysis of treatments and outcomes in EGFRm NSCLC patients highlights the importance of using the most efficacious therapies currently available in 1L to reduce attrition and improve patient outcomes.

Citing Articles

Cancer care treatment attrition in adults: Measurement approaches and inequities in patient dropout rates - a rapid review.

Shand J, Stovold E, Goulding L, Cheema K BMC Cancer. 2024; 24(1):1345.

PMID: 39482591 PMC: 11528991. DOI: 10.1186/s12885-024-13096-7.

The Role of Stem Cell Factor, Epidermal Growth Factor and Angiopoietin-2 in HBV, HCV, HCC and NAFLD.

Radmanic L, Zidovec-Lepej S Life (Basel). 2022; 12(12).

PMID: 36556437 PMC: 9786337. DOI: 10.3390/life12122072.

Perspectives for Cancer Care and Research in Central and Eastern Europe.

Zielinski C, Cufer T, Seruga B, Jassem J, Dediu M, Thallinger C Oncol Res Treat. 2022; 46(3):80-88.

PMID: 36463856 PMC: 10015746. DOI: 10.1159/000528487.

References

Han G, Bi J, Tan W, Wei X, Wang X, Ying X . A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?. Oncotarget. 2016; 7(35):56998-57010. PMC: 5302968. DOI: 10.18632/oncotarget.10933. View

Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4(9):1046-61. PMC: 4315625. DOI: 10.1158/2159-8290.CD-14-0337. View

Lee C, Ahmed I, Miao E, Chung S, Patel K, Kohn N . A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study. J Oncol Pharm Pract. 2021; 28(5):1140-1151. DOI: 10.1177/10781552211020798. View

Pereira I, Gaspar C, Pina M, Azevedo I, Rodrigues A . Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Cureus. 2021; 12(12):e12128. PMC: 7810175. DOI: 10.7759/cureus.12128. View

Szumera-Cieckiewicz A, Olszewski W, Tysarowski A, Kowalski D, Glogowski M, Krzakowski M . EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol. 2013; 6(12):2800-12. PMC: 3843260. View

Pluzanski A, Krzakowski M, Kowalski D, Dziadziuszko R . Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients. ESMO Open. 2020; 5(6):e001011. PMC: 7640619. DOI: 10.1136/esmoopen-2020-001011. View

Reale M, Chiari R, Tiseo M, Vitiello F, Barbieri F, Cortinovis D . Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. Lung Cancer. 2019; 140:71-79. DOI: 10.1016/j.lungcan.2019.12.006. View

Zhang Y, Yuan J, Wang K, Fu X, Han X, Threapleton D . The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016; 7(48):78985-78993. PMC: 5346692. DOI: 10.18632/oncotarget.12587. View

Gelatti A, Drilon A, Santini F . Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019; 137:113-122. PMC: 7478849. DOI: 10.1016/j.lungcan.2019.09.017. View

10.

Tan A, Teh Y, Lai G, Tan D . Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC). Expert Rev Anticancer Ther. 2019; 19(6):431-435. DOI: 10.1080/14737140.2019.1604228. View

11.

Huang Y, Hsu K, Tseng J, Chen K, Hsu C, Su K . The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. Cancer Res Treat. 2018; 50(4):1294-1303. PMC: 6192936. DOI: 10.4143/crt.2017.512. View

12.

Magios N, Bozorgmehr F, Volckmar A, Kazdal D, Kirchner M, Herth F . Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Ther Adv Med Oncol. 2021; 13:1758835921996509. PMC: 8366107. DOI: 10.1177/1758835921996509. View

13.

Halliday P, Blakely C, Bivona T . Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Curr Oncol Rep. 2019; 21(3):21. DOI: 10.1007/s11912-019-0770-x. View

14.

Shah R, Girard N, Nagar S, Griesinger F, Roeper J, Davis K . European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review. Drugs Real World Outcomes. 2021; 8(4):537-545. PMC: 8605952. DOI: 10.1007/s40801-021-00261-8. View

15.

Reungwetwattana T, Nakagawa K, Cho B, Cobo M, Cho E, Bertolini A . CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018; :JCO2018783118. DOI: 10.1200/JCO.2018.78.3118. View

16.

Gridelli C, Rossi A, Carbone D, Guarize J, Karachaliou N, Mok T . Non-small-cell lung cancer. Nat Rev Dis Primers. 2016; 1:15009. DOI: 10.1038/nrdp.2015.9. View

17.

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

18.

Ramalingam S, Yang J, Lee C, Kurata T, Kim D, John T . Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2017; 36(9):841-849. DOI: 10.1200/JCO.2017.74.7576. View

19.

Stanic K, Zwitter M, Hitij N, Kern I, Sadikov A, Cufer T . Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol. 2014; 48(2):173-83. PMC: 4078036. DOI: 10.2478/raon-2014-0016. View

20.

Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Giaj Levra M . Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5):v1-v27. DOI: 10.1093/annonc/mdw326. View